[go: up one dir, main page]

PE20140239A1 - Derivados de 1,4-oxazepano - Google Patents

Derivados de 1,4-oxazepano

Info

Publication number
PE20140239A1
PE20140239A1 PE2013000801A PE2013000801A PE20140239A1 PE 20140239 A1 PE20140239 A1 PE 20140239A1 PE 2013000801 A PE2013000801 A PE 2013000801A PE 2013000801 A PE2013000801 A PE 2013000801A PE 20140239 A1 PE20140239 A1 PE 20140239A1
Authority
PE
Peru
Prior art keywords
oxazepan
oxazepane
compounds
dichlorophenyl
methyl
Prior art date
Application number
PE2013000801A
Other languages
English (en)
Inventor
Yuji Ishichi
Masami Yamada
Taku Kamel
Ikuo Fujimori
Yoshihisa Nakada
Tomoya Yukawa
Nobuki Sakauchi
Yusuke Ohba
Tetsuya Tsukamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20140239A1 publication Critical patent/PE20140239A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 1,4-OXAZEPANO DE FORMULA (I) DONDE A ES UN ANILLO AROMATICO DE 6 MIEMBROS; EL ANILLO B ES UN COMPUESTO DE FORMULA (B1), (B2), (B3), ENTRE OTROS, EN DONDE R ES HIDROXI, CN, CARBOXI, AMINO, ALQUILO(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{[(6S,7R)-7-(3,4-DICLOROFENIL)-1,4-OXAZEPAN-6-IL]METIL}-2-METOXIACETAMIDA; N-[(6R,7S)-7-(3,4-DICLOROFENIL)-1,4-OXAZEPAN-6-IL]ACETAMIDA; ACIDO 1-{[(6S,7R)-7-(4-CLORO-3-FLUOROFENIL)-1,4-OXAZEPAN-6-IL]METIL}-2-OXO-1,2-DIHIDROPIRIDIN-3-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA DE LA RECEPTACION DE MONOAMINA SIENDO UTILES EN EL TRATAMIENTO DE DEPRESION, ANSIEDAD, TRASTORNO CLIMATERICO
PE2013000801A 2010-10-07 2011-10-05 Derivados de 1,4-oxazepano PE20140239A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010227864 2010-10-07
JP2011175336 2011-08-10

Publications (1)

Publication Number Publication Date
PE20140239A1 true PE20140239A1 (es) 2014-03-07

Family

ID=44906302

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000801A PE20140239A1 (es) 2010-10-07 2011-10-05 Derivados de 1,4-oxazepano

Country Status (26)

Country Link
US (2) US8722662B2 (es)
EP (1) EP2625170A1 (es)
JP (1) JP5873487B2 (es)
KR (1) KR20130116073A (es)
CN (1) CN103261176B (es)
AR (1) AR083313A1 (es)
AU (1) AU2011313150A1 (es)
BR (1) BR112013008420A2 (es)
CA (1) CA2813911A1 (es)
CL (1) CL2013000927A1 (es)
CO (1) CO6700872A2 (es)
CR (1) CR20130158A (es)
DO (1) DOP2013000074A (es)
EA (1) EA201390491A1 (es)
EC (1) ECSP13012593A (es)
GE (1) GEP20156295B (es)
IL (1) IL225189A0 (es)
MX (1) MX2013003749A (es)
NZ (1) NZ608499A (es)
PE (1) PE20140239A1 (es)
PH (1) PH12013500657A1 (es)
SG (1) SG188346A1 (es)
TW (1) TW201242956A (es)
UY (1) UY33650A (es)
WO (1) WO2012046882A1 (es)
ZA (1) ZA201302112B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6137193B2 (ja) * 2011-12-21 2017-05-31 小野薬品工業株式会社 第ＸＩａ因子阻害剤としての新規ピリジノンおよびピリミジノン誘導体
WO2015011087A1 (de) * 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma
CN105693652B (zh) * 2014-11-27 2019-01-08 常州合全药业有限公司 一种4-叔丁基-5-乙基-6-氧亚基-1,4-噁吖庚环-4,5-二甲酸基酯的合成方法
JP6610562B2 (ja) 2014-12-10 2019-11-27 小野薬品工業株式会社 ジヒドロインドリジノン誘導体
CA2984565A1 (en) 2015-05-08 2016-11-17 Vertellus Holdings Llc Processes for converting carboxamides to thiocarboxamides
WO2024251807A1 (en) * 2023-06-08 2024-12-12 Cybin Irl Limited Companion animal treatments
WO2025006617A2 (en) * 2023-06-27 2025-01-02 Armgo Pharma, Inc. Agents for treating disorders involving ryanodine receptors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018222A (en) 1956-08-28 1962-01-23 Ravensberg G M B H Central stimulant and appetite depressant composition
US4010166A (en) 1974-11-25 1977-03-01 Ciba-Geigy Corporation 1,4-Oxazepines
DE3242923A1 (de) 1982-11-20 1984-05-24 Basf Ag, 6700 Ludwigshafen 7-phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepine, ihre herstellung und verwendung
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
DK0929574T3 (da) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
US6861419B2 (en) 2000-04-18 2005-03-01 Cytovia, Inc. Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
GB0229743D0 (en) * 2002-12-20 2003-01-29 Arakis Ltd Novel benzoxazocines
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP1996202A1 (en) * 2006-03-10 2008-12-03 AstraZeneca AB Chemical compounds
WO2007137953A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Benzazepine derivatives as monoamine reuptake inhibitors
WO2008062905A2 (en) 2006-11-24 2008-05-29 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
GB0721178D0 (en) 2007-10-29 2007-12-05 Glaxo Group Ltd Chemical compounds
WO2009119528A1 (ja) 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
WO2010016554A1 (ja) 2008-08-07 2010-02-11 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
GEP20156295B (en) 2015-06-10
IL225189A0 (en) 2013-06-27
US20120088748A1 (en) 2012-04-12
EP2625170A1 (en) 2013-08-14
PH12013500657A1 (en) 2013-05-06
DOP2013000074A (es) 2014-07-31
AU2011313150A1 (en) 2013-04-18
UY33650A (es) 2012-04-30
CA2813911A1 (en) 2012-04-12
JP2013538786A (ja) 2013-10-17
JP5873487B2 (ja) 2016-03-01
EA201390491A1 (ru) 2013-11-29
ZA201302112B (en) 2013-12-23
CL2013000927A1 (es) 2013-09-13
CN103261176A (zh) 2013-08-21
MX2013003749A (es) 2013-05-09
NZ608499A (en) 2015-03-27
TW201242956A (en) 2012-11-01
KR20130116073A (ko) 2013-10-22
US8722662B2 (en) 2014-05-13
SG188346A1 (en) 2013-04-30
US20130267494A1 (en) 2013-10-10
CO6700872A2 (es) 2013-06-28
ECSP13012593A (es) 2013-07-31
CN103261176B (zh) 2015-06-03
BR112013008420A2 (pt) 2016-06-28
AR083313A1 (es) 2013-02-13
WO2012046882A1 (en) 2012-04-12
CR20130158A (es) 2013-05-03

Similar Documents

Publication Publication Date Title
PE20140239A1 (es) Derivados de 1,4-oxazepano
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA201390723A1 (ru) Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep
MX2011008501A (es) Compuestos heterociclicos fusionados que contienen nitrogeno y su uso como inhibidores de la produccion de beta-amiloide.
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
TN2011000400A1 (en) Inhibitors of beta-secretase
MY163498A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
PE20140011A1 (es) Compuestos y composiciones novedosos para la inhibicion de nampt
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
CL2009001152A1 (es) Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
IN2014MN02106A (es)
PE20140966A1 (es) Quinazolincarboxamida azetidinas
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
PH12012501643A1 (en) Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
EA201390488A1 (ru) Новые агонисты gpr 119
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
PE20120112A1 (es) Compuestos heterociclicos inhibidores de topoisomerasas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal